Close

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

Shire news

30 Jul 2014 Updated Rule 2.10 Announcement
29 Jul 2014 Director/PDMR Share Dealings
28 Jul 2014 Updated Rule 2.10 Announcement
24 Jul 2014 Updated Rule 2.10 Announcement
23 Jul 2014 Shire Enters Strategic Licensing and Collaboration Agreement with ArmaGen
23 Jul 2014 Updated Rule 2.10 Announcement
21 Jul 2014 Updated Rule 2.10 Announcement
18 Jul 2014 Recommended combination of Shire and AbbVie
18 Jul 2014 Shire delivers record quarterly revenues and Non GAAP diluted earnings per ADS up 42%
17 Jul 2014 Top-Line Results From Two Head-to-Head Studies Comparing Vyvanse® (lisdexamfetamine dimesylate), CII, With Concerta® (methylphenidate HCl), CII, in Adolescents with ADHD
17 Jul 2014 Updated Rule 2.10 Announcement
15 Jul 2014 Updated Rule 2.10 Announcement
14 Jul 2014 Update re: AbbVie Proposal
11 Jul 2014 Statement re: Media Speculation
11 Jul 2014 Updated Rule 2.10 Announcement
09 Jul 2014 Updated Rule 2.10 Announcement
08 Jul 2014 Statement re: AbbVie Announcement
07 Jul 2014 Updated Rule 2.10 Announcement
03 Jul 2014 Form 8 (OPD) AbbVie Inc.
03 Jul 2014 Form 8 (OPD) Shire plc
03 Jul 2014 Updated Rule 2.10 Announcement
01 Jul 2014 Total Voting Rights
01 Jul 2014 FORM 8 (DD) - Shire plc
01 Jul 2014 FORM 8 (DD) - Shire plc
01 Jul 2014 FORM 8 (DD) - Shire plc
01 Jul 2014 FORM 8 (DD) - Shire plc
01 Jul 2014 FORM 8 (DD) - Shire plc
01 Jul 2014 FORM 8 (DD) - Shire plc
01 Jul 2014 FORM 8 (DD) - Shire plc
01 Jul 2014 FORM 8 (DD) - Shire plc
01 Jul 2014 Updated Rule 2.10 Announcement
30 Jun 2014 Director/PDMR Share Dealings
30 Jun 2014 Shire receives US$248 million cash refund from the Canadian revenue authorities, expects a further US$162 million in late 2014
27 Jun 2014 Updated Rule 2.10 Announcement
26 Jun 2014 Updated Rule 2.10 Announcement
25 Jun 2014 Shire Comments on AbbVie's Unchanged Proposal
25 Jun 2014 Vyvanse Patents Found to Be Infringed and Valid by U.S. District Court
23 Jun 2014 The Path to US$10 Billion in Product Sales by 2020
23 Jun 2014 Shire to host investor call
20 Jun 2014 Shire Update Call for Investors
20 Jun 2014 Shire Confirms Rejection of AbbVie Proposal
18 Jun 2014 Shire Launches Excellence in ADHD Patient Group Awards
12 Jun 2014 Shire Agrees to FDA Request to Conduct Clinical Trials Investigating the Potential Use of Vyvanse® (lisdexamfetamine dimesylate) in Preschool-Age Children with ADHD
10 Jun 2014 Shire to participate at the Goldman Sachs 35th Annual Global Healthcare Conference
02 Jun 2014 Shire to present at the Jefferies 2014 Global Healthcare Conference
02 Jun 2014 Total Voting Rights
23 May 2014 Block Listing Six Monthly Return
16 May 2014 Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults
12 May 2014 Shire adds to rare disease portfolio with acquisition of Lumena Pharmaceuticals, bringing late stage compounds for rare GI/hepatic conditions
02 May 2014 Shire to Present Scientific Data at American Psychiatric Association Annual Meeting
01 May 2014 Shire delivers a strong start to 2014 and increases full year guidance
01 May 2014 Total Voting Rights
30 Apr 2014 Shire Announces Updates from Phase 3 Clinical Program for Lifitegrast in Adults with Dry Eye Disease
29 Apr 2014 Results of the 2014 Annual General Meeting (36KB PDF)
17 Apr 2014 First quarter 2014 results date notification - May 1, 2014
15 Apr 2014 Pre-quarterly Results Communication
01 Apr 2014 Director/PDMR Share Dealings
01 Apr 2014 Total Voting Rights
31 Mar 2014 Director/PDMR Share Dealings
27 Mar 2014 Shire submits INTUNIV® (guanfacine extended release) Marketing Authorisation Application to EMA
27 Mar 2014 2013 Annual Report - DTR 6.3.5 Disclosure
14 Mar 2014 Director Declaration
14 Mar 2014 Shire Pharmaceuticals Initiates Voluntary Nationwide Recall Of One Batch, Packaged into Three Lots, of VPRIV® (velaglucerase alfa for injection)
07 Mar 2014 Director/PDMR Shareholding
06 Mar 2014 Director/PDMR Shareholding
04 Mar 2014 Shire to present at the Cowen and Company 34th Annual Health Care Conference
03 Mar 2014 Elections for Interim Dividend in Respect of the Six Months to December 31, 2013
03 Mar 2014 Director/PDMR Shareholding
03 Mar 2014 Total Voting Rights
28 Feb 2014 Shire Recognizes Rare Disease Day 2014
25 Feb 2014 ViroPharma announces results of tender offer for its 2.00% Convertible Senior Notes Due 2017 (49KB PDF)
25 Feb 2014 STATEMENT RELATING TO SHIRE’S VPRIV® (VELAGLUCERASE ALFA FOR INJECTION) PRESS RELEASE DATED JUNE 28, 2012
21 Feb 2014 Director’s Share Dealings
20 Feb 2014 Director's Share Dealings
17 Feb 2014 Director's Share Dealings
13 Feb 2014 Chief Financial Officer Graham Hetherington to step down
13 Feb 2014 Shire delivers double digit product sales growth and 23% increase in Non GAAP earnings per ADS
06 Feb 2014 Shire Reports Top-line Results from Two Phase 3 Studies for Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) as an Adjunctive Treatment for Adults with Major Depressive Disorder
04 Feb 2014 Historical income statements recast for DERMAGRAFT discontinued operations
03 Feb 2014 Total Voting Rights
30 Jan 2014 Full Year 2013 results date notification – February 13, 2014
24 Jan 2014 ViroPharma announces tender offer for its 2.00% Convertible Senior Notes Due 2017 (57KB PDF)
24 Jan 2014 Shire successfully completes tender offer for ViroPharma
23 Jan 2014 Susan Kilsby to succeed Matthew Emmens as Chairman of Shire
17 Jan 2014 Cancellation of listing and admission to trading of Shire plc Convertible Bonds due 2014
17 Jan 2014 Shire Executes Agreement to Divest DERMAGRAFT®
15 Jan 2014 Shire waives OFT condition relating to the acquisition of ViroPharma Inc.
14 Jan 2014 Guidance Update
10 Jan 2014 Shire extends tender offer for ViroPharma
02 Jan 2014 Total Voting Rights

Did you know...

We have developed a
version of this web site
that is suitable for your
portable device
.